Veradigm Stock

Veradigm Equity

The The Equity of Veradigm (MDRX) as of Aug 5, 2026 is 1.02 B USD. In the previous year, The Equity was 1.02 B USD — a change of 0.00% (lower).

Equity

1.02 BUSD

YoY

0.00%

Last updated:

In 2026, Veradigm's equity was 1.02 B USD, a 0.00% increase from the 1.02 B USD equity in the previous year.

Access this data via the Eulerpool API

Veradigm Stock analysis

What does Veradigm do? Allscripts Healthcare Solutions Inc is one of the leading companies in the digital healthcare sector in the USA. The company was founded in 1982 and has since become one of the most important providers of IT solutions in healthcare. Allscripts supports healthcare providers in improving patient care and efficiency through the development and provision of innovative software and IT solutions. The business model of Allscripts is based on the development and sale of web-based software solutions for medical documentation and hospital management. These solutions are mainly distributed to hospitals and practices through subscriptions or licenses. Allscripts offers a variety of products that focus on various areas of medical care. One of the main divisions of the company is the electronic health records system (EHR). This system allows for the electronic recording, storage, and management of medical data and information. This enables healthcare providers to quickly and easily access patient information and document important diagnoses and treatments. Another important division of Allscripts is the Revenue Cycle Management (RCM), which optimizes billing and payment processes in hospitals and practices. In addition, Allscripts also offers solutions for telemedicine, including patient portal applications, remote patient monitoring systems, and mobile apps for patients and providers. Allscripts is based in Chicago and employs over 10,000 employees in various countries. The company also maintains partnerships with other companies in healthcare to facilitate and improve the complexity of digital transformation in the healthcare market. This includes companies like Microsoft, who work together with Allscripts on the development of artificial intelligence for healthcare applications. Allscripts' portfolio of offerings is very broad and provides customers with a variety of software solutions for different areas of medical care. The products are particularly characterized by their user-friendly interfaces, flexibility, and scalability. This allows customers to customize the solutions to their specific needs and consider future requirements. However, some products have been criticized for their expandability, poor design, and slow loading times. Recently, Allscripts has made a number of investments in research and development to address these issues and optimize the applications. In summary, Allscripts Healthcare Solutions Inc is considered one of the leading providers of software and IT solutions in healthcare in the USA. Thanks to a wide range of products and close collaboration with partners in healthcare, Allscripts is able to offer its customers innovative and scalable solutions that help them optimize their business processes and improve the quality of their medical care. Veradigm is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Veradigm's Equity

Veradigm's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Veradigm's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Veradigm's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Veradigm's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Veradigm’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Veradigm stock

The Equity of Veradigm is 1.02 B USD in 2026.

The Equity of Veradigm changed from 1.02 B USD to 1.02 B USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Veradigm since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Veradigm historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Veradigm

All Key Metrics — Veradigm